GlassScriptPhysician profile
James Craig Webb
NPI 1104834993
$6,214.89
in general payments reported to CMS, 2019-2025
51 companies · $836 in 2025
The $836 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $981 · 2020: $560 · 2021: $741 · 2022: $1,269 · 2023: $1,001 · 2024: $827 · 2025: $836.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,664.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,664.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,066.52 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Amgen INC. | $886.96 | 2019-2025 | Evenity, Prolia, Otezla |
| Novo Nordisk INC | $550.25 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $490.77 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $477.36 | 2019-2025 | |
| Axsome Therapeutics, INC. | $214.54 | 2022-2025 | Sunosi, Auvelity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $211.78 | 2020-2024 | Jardiance, Ofev, Stiolto Respimat |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $158.93 | 2019-2024 | Xifaxan |
| Lilly USA, LLC | $154.55 | 2019-2024 | Mounjaro, Zepbound, Emgality |
| Astrazeneca Pharmaceuticals LP | $151.28 | 2020-2025 | Breztri, Farxiga, Airsupra |
| Otsuka America Pharmaceutical, INC. | $138.25 | 2019-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $123.40 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $122.30 | 2019-2022 | |
| Astellas Pharma US INC | $102.44 | 2021-2025 | Veozah |
| Harmony Biosciences LLC | $93.67 | 2021 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Webb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.